Detalhe da pesquisa
1.
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
J Immunol
; 184(10): 5654-62, 2010 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20400704
2.
PILAR is a novel modulator of human T-cell expansion.
Blood
; 112(4): 1259-68, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18550855
3.
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.
Oncotarget
; 1(5): 329-38, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21113407
4.
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
Cancer Res
; 69(18): 7329-37, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19738057
5.
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.
Cancer Res
; 68(18): 7684-91, 2008 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18768667